Millions of women worldwide suffer from painful urinary tract infections (UTIs), and a growing number of these infections have become resistant to current antibiotics. But there's a hope still on the horizon: the U.S. Food and Drug Administration (FDA) has just approved a new antibiotic for UTIs, the first in nearly 30 years, offering hope for those battling antibiotic-resistant infections.
The new drug, Gepotidacin sold under brand name Blujepa, manufactured by GSK, has been approved for use in women and girls aged 12 and older with uncomplicated UTIs (uUTIs), the most common type of infection among women.
